01 / Mechanism

An incomplete picture.

Unlike classical stimulants (amphetamine, methylphenidate), modafinil does not produce strong, broad-spectrum monoamine release. Its best-characterized action is weak inhibition of the dopamine transporter (DAT) — enough to elevate extracellular dopamine in the nucleus accumbens and prefrontal cortex without the surge profile of stimulants. This DAT activity is now considered necessary, though probably not sufficient, for its wake-promoting effect [Volkow 2009].

Other contributors include activation of orexin/hypocretin neurons in the lateral hypothalamus (the same system that goes missing in narcolepsy), increased histamine release from the tuberomammillary nucleus, and downstream effects on glutamate and GABA balance in arousal circuits [Minzenberg 2008]. The result is wake-promotion without the same drive on locomotion, anxiety, and reward as stimulants — which is why it does not feel like Adderall and why abuse liability is genuinely lower (though not zero).

Modafinil is a racemic mixture of R- and S-enantiomers. The R-enantiomer (armodafinil, brand Nuvigil) has a longer half-life (~15 hours vs. ~4 hours for S-modafinil) and produces a smoother plasma curve from a single morning dose. Clinically, 150 mg armodafinil and 200 mg modafinil are approximately equivalent.

02 / Dosing

Approved indications.

Indication	Dose	Timing	Note
Narcolepsy	200 mg daily	Morning	Some titrate to 400 mg
OSA (adjunct to CPAP)	200 mg daily	Morning	Not a CPAP replacement
Shift-work sleep disorder	200 mg daily	1 hr before shift	SWSD = shift-work sleep disorder
Off-label cognition	50–200 mg occasional	Morning	Larger doses do not produce larger benefit
Armodafinil (R-modafinil)	150 mg daily	Morning	Smoother plasma curve

Late-day dosing is the most common self-inflicted mistake

Half-life is 12–15 hours. Any dose taken after early afternoon disrupts the same-night sleep. The drug is a tool for the front half of the day; using it to push past 8 PM is how people stay up until 4 AM and then need it again tomorrow.

03 / Off-label cognition

What it actually does in healthy people.

Battleday and Brem's 2015 systematic review pooled trials in non-sleep-deprived healthy adults and concluded that modafinil reliably improves executive function, with smaller and less consistent signals on attention and learning. Benefits were largest on tasks of greater complexity — the more cognitively loaded the test, the more visible the drug effect [Battleday 2015].

In sleep-deprived adults, the effect size is much larger and more consistent. This is the use case for which the military funded most of the early modafinil research and where the drug performs closest to its stated wakefulness label. Community use in graduate students, software engineers, and shift workers tracks this distribution — most "modafinil helped me write" reports involve modest sleep restriction.

Tolerance to wakefulness is limited; tolerance to subjective "edge" is not. Many regular users describe a fading novelty effect after the first few months. Daily use is also socially expensive — sleep is the underlying solution, and modafinil makes sleep deficit easier to ignore, not smaller.

04 / Drug interactions

The under-discussed risks.

CYP3A4 induction → hormonal contraceptive failure. Modafinil and armodafinil induce CYP3A4, which metabolizes the progestin (and to a lesser extent estrogen) component of oral, transdermal, ring, and implant contraceptives. Estimated reduction in hormone exposure is in the range of 18%. Guidance recommends an alternative or backup non-hormonal method during use and for one month after discontinuation. Copper IUD, levonorgestrel IUS, and depot progestogen injections are not affected.
CYP2C19 inhibition. Increased exposure to substrates such as phenytoin, diazepam, omeprazole, propranolol.
Reduced clearance of TCAs and SSRIs. Watch for sertraline, fluoxetine, clomipramine combinations.
Warfarin. Plasma protein binding interaction; INR monitoring needed if co-administered.
Cyclosporine, tacrolimus. Decreased exposure via CYP3A4 induction — transplant-relevant.
Pregnancy. 2019 EMA review concluded modafinil should not be used in pregnancy due to congenital malformation signal.

05 / Side effects

Common and serious.

Headache (~34%). The single most common complaint. Often resolves with hydration and a few doses.
Insomnia. Almost entirely a function of late-day dosing.
Nausea, decreased appetite. Usually mild; appetite suppression is dose-related.
Anxiety, irritability. Reported in a minority — more common in people with pre-existing anxiety disorder.
Tachycardia, mild blood pressure elevation. Clinically modest in healthy people; relevant in pre-existing cardiovascular disease.
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (SJS/TEN). Rare but severe skin reactions. Any new rash on modafinil — stop immediately and seek care. The FDA added this warning after pediatric case reports.
Psychiatric (rare). Mania, psychosis in susceptible individuals. Caution in bipolar history.

06 / Cost

Generic economics.

Source	Form	~Monthly cost (USD)	Note
Brand	Provigil 200 mg	$1,200+ cash	Rarely paid; covered by some plans
Generic	Modafinil 200 mg	$30–$80 with discount card	What most prescriptions cost
Brand	Nuvigil 150 mg (armodafinil)	$900+ cash	Smoother curve, often covered
Generic	Armodafinil 150 mg	$40–$100 with discount	Slightly pricier than modafinil

07 / Bottom line

Where modafinil fits.

Modafinil is a genuine tool for excessive daytime sleepiness with a clean label, decades of post-marketing data, and a real but modest cognitive signal in non-sleep-deprived users. It is not a substitute for sleep, and the contraceptive interaction is under-counseled by many prescribers. People using it occasionally with awareness of the interaction profile are in the safest position; daily off-label use without clinical oversight is where the SJS warning, the cardiovascular signal, and the contraceptive risk start to matter.

See the sleep topic hub for context on where wakefulness agents sit alongside CPAP, light exposure, and sleep schedule interventions.

08 / References

The evidence base.

Battleday RM, Brem AK. Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: A systematic review. European Neuropsychopharmacology, 2015;25(11):1865–1881. [Battleday 2015]
Volkow ND, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain. JAMA, 2009;301(11):1148–1154. [Volkow 2009]
Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 2008;33:1477–1502. [Minzenberg 2008]
Robertson P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clinical Pharmacokinetics, 2003;42(2):123–137. [Robertson 2003]
Roth T, et al. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome. Clinical Therapeutics, 2006;28(5):689–706. [Roth 2006]
Pizza F, et al. Modafinil and adverse events: a systematic review. Sleep Medicine Reviews, 2022;65:101683. [Pizza 2022]
EMA Pharmacovigilance Risk Assessment Committee. Modafinil: risk of congenital malformations during pregnancy. European Medicines Agency, 2019. [EMA 2019]
US FDA. Provigil (modafinil) prescribing information — black-box and warnings, including SJS/TEN. Revised label. [FDA label]

About this profile

Last reviewed against evidence: 2026-05-12. This profile is editorial reference content, not sponsored. Wellness Radar does not carry affiliate links for prescription drugs. Educational reference, not a prescription — modafinil is a scheduled, prescription-only medication; decisions belong with a clinician familiar with your medication list and history.

Modafinil